COVID-19 Vaccines: Development, Efficacy, Safety, and Global Distribution

Purevbat Bazarjav[1], Ankhbayar Sandagdorj[1], Enkhbold Sereejav[2], Erdembileg Tsevegmid[2], Oyunsuren Enebish[2], Bayarbold Dangaasuren[2], Dashpagma Otgonbayar[1], Bilegtsaikhan Tsolmon[1,3], Tsogzolmaa Ganbold[1]

[1]The National Center for Diseases, Ulaanbaatar, Mongolia
[2]Ministry of Health, Ulaanbaatar, Mongolia
[3]Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

E-mail: purevbatbazarjav@gmail.com; ankhbayarsnicmng@gmail.com; Bilegtsaikhan@gmail.com

*Corresponding Authors: Bilegtsaikhan Tsolmon, National Center for Communicable Diseases of Mongolia, Nam Yan Ju Street, Ulaanbaatar 210648, Mongolia.

Abstract: The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has had a profound impact on global public health, healthcare systems, and economies. The development and deployment of safe and effective vaccines have been a critical component of the global response to the pandemic. In this review, we provide an overview of COVID-19 vaccine development, including the various vaccine platforms used, the evaluation of vaccine efficacy and safety, and the challenges and strategies related to global vaccine distribution and administration. We also discuss the implications of emerging SARS-CoV-2 variants for vaccine effectiveness and future research directions.
Keywords: COVID-19, vaccines, efficacy.

Introduction

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to millions of infections and deaths worldwide. The rapid development and deployment of safe and effective vaccines have been central to the global response to the pandemic, offering hope for controlling viral transmission, reducing disease severity, and ultimately bringing an end to the public health crisis[1, 2].

The development of COVID-19 vaccines has been unprecedented in terms of speed and scale, with multiple vaccines authorized for emergency use within a year of the virus's initial identification. This achievement can be attributed to advances in vaccine technology, international collaboration, and substantial financial investments. However, challenges remain in ensuring global vaccine access, addressing vaccine hesitancy, and adapting vaccines to emerging SARS-CoV-2 variants[3-5].

This review aims to provide a comprehensive overview of COVID-19 vaccine development, including the various vaccine platforms used, the evaluation of vaccine efficacy and safety, and the challenges and strategies related to global vaccine distribution and administration. We will also discuss the implications of emerging SARS-CoV-2 variants for vaccine effectiveness and future research directions.

COVID-19 Vaccine Platforms

Several vaccine platforms have been employed in the development of COVID-19 vaccines, including: Messenger RNA (mRNA) vaccines, viral vector vaccines, Inactivated virus vaccines, and protein subunit vaccines (Figure. 1). mRNA vaccines, such as the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines, use a small piece

of the virus's genetic material (mRNA) to instruct cells to produce a harmless piece of the SARS-CoV-2 spike protein. This triggers an immune response that produces antibodies against the virus. mRNA vaccines have demonstrated high efficacy in clinical trials and have been authorized for emergency use in several countries[6, 7]. Viral vector vaccines use a harmless virus (not SARS-CoV-2) to deliver a gene that encodes a SARS-CoV-2 protein, typically the spike protein, to stimulate an immune response. Examples of viral vector vaccines include the Oxford-AstraZeneca (ChAdOx1 nCoV-19) and Johnson & Johnson (Ad26.COV2.S) vaccines. These vaccines have shown varying degrees of efficacy in clinical trials and have also been authorized for emergency use in several countries[8-10]. Inactivated virus vaccines, such as the Sinovac (CoronaVac) and Sinopharm (BBIBP-CorV) vaccines, contain whole SARS-CoV-2 viruses that have been inactivated, rendering them incapable of causing disease. These vaccines stimulate an immune response against the virus. Inactivated virus vaccines have demonstrated varying levels of efficacy in clinical trials and have been authorized for use in several countries[11, 12]. Protein subunit vaccines, such as the Novavax (NVX-CoV2373) vaccine, contain harmless fragments of the SARS-CoV-2 spike protein, which stimulate an immune response without causing disease. Protein subunit vaccines are generally well-tolerated and have shown promise in clinical trials, with some receiving emergency use authorization in various countries[13, 14].


Figure 1. A schematic representation is shown of the classical vaccine platforms that are commonly used for COVID-19 vaccines[15].

Evaluation of COVID-19 Vaccine Efficacy and Safety
The evaluation of COVID-19 vaccine efficacy and safety has been conducted through multiple phases of clinical trials.
Phase 1 trials: These small-scale trials are designed to assess the safety and tolerability of the vaccine, as well as the optimal dosage.
Phase 2 trials: These larger trials aim to evaluate the vaccine's safety, immunogenicity (the ability to provoke an immune response), and preliminary efficacy in a more diverse population.
Phase 3 trials: In these large-scale trials, the vaccine is administered to tens of thousands of participants to determine its efficacy in preventing COVID-19 and its safety profile. The results of Phase 3 trials are used to support applications for emergency use authorization or regulatory approval[16, 17].
The efficacy of COVID-19 vaccines is primarily measured by their ability to prevent symptomatic infection, severe disease, hospitalization, and death. The vaccines authorized for emergency use have demonstrated varying levels of efficacy in clinical trials:
Pfizer-BioNTech (BNT162b2): This mRNA vaccine has demonstrated an efficacy of 95% in preventing symptomatic COVID-19 infection in Phase 3 trials[18].
Moderna (mRNA-1273): Another mRNA vaccine, Moderna's candidate has shown an efficacy of 94.1% in preventing symptomatic COVID-19 infection in Phase 3 trials[19].

Oxford-AstraZeneca (ChAdOx1 nCoV-19): This viral vector vaccine has an overall efficacy of 70.4% in preventing symptomatic COVID-19 infection, with varying efficacy depending on the dosing regimen used[20].

Johnson & Johnson (Ad26.COV2.S): This single-dose viral vector vaccine has demonstrated an efficacy of 66.3% in preventing moderate to severe COVID-19 infection in Phase 3 trials.

Sinovac (CoronaVac): This inactivated virus vaccine has shown varying levels of efficacy in different clinical trials, ranging from 50.4% to 83.5% in preventing symptomatic COVID-19 infection[21].

Sinopharm (BBIBP-CorV): Another inactivated virus vaccine, Sinopharm's candidate has demonstrated an efficacy of 78.1% in preventing symptomatic COVID-19 infection in Phase 3 trials[22].

Novavax (NVX-CoV2373): This protein subunit vaccine has shown an overall efficacy of 89.7% in preventing symptomatic COVID-19 infection in Phase 3 trials[23].

In addition to efficacy, the safety of COVID-19 vaccines has been carefully evaluated in clinical trials, with most vaccines demonstrating a favorable safety profile. Common side effects include pain at the injection site, fatigue, headache, muscle pain, chills, fever, and nausea. Serious adverse events have been rare, but ongoing post-authorization surveillance is essential to monitor vaccine safety in real-world settings.

Global Vaccine Distribution and Administration Challenges

Ensuring the equitable distribution and administration of COVID-19 vaccines worldwide is critical to controlling the pandemic. However, several challenges have emerged, including vaccine supply, global equity, distribution infrastructure, vaccine hesitancy, emerging SARS-CoV-2 variants. High demand and limited production capacity have led to supply constraints, particularly for mRNA vaccines, which require specialized manufacturing facilities[24]. Wealthier countries have secured a disproportionate share of vaccine doses, leading to disparities in vaccine access between high-income and low-income countries[25]. The storage and transportation requirements of some vaccines, particularly mRNA vaccines requiring ultra-cold storage, present logistical challenges in some regions, particularly in low-resource settings[26]. Public concerns about the safety and efficacy of COVID-19 vaccines, fueled in part by misinformation and mistrust, have led to hesitancy among some individuals to get vaccinated[27]. The emergence of new viral variants with the potential to reduce vaccine effectiveness necessitates ongoing surveillance, as well as the adaptation of vaccines and public health strategies[28].

To address these challenges, several strategies have been proposed and implemented.

COVAX: The COVAX initiative, led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), aims to ensure equitable global access to COVID-19 vaccines by pooling resources and negotiating with manufacturers on behalf of participating countries[29].

Technology transfer and licensing agreements: These agreements can help increase vaccine production capacity by allowing manufacturers in low- and middle-income countries to produce vaccines developed elsewhere[30].

Strengthening distribution infrastructure: Investments in cold chain storage, transportation, and healthcare worker training can help facilitate vaccine distribution in low-resource settings.

Public health campaigns: These campaigns are essential to build trust in vaccines and address concerns related to safety and efficacy, particularly in communities with high levels of vaccine hesitancy[31].

Surveillance and vaccine adaptation: Ongoing surveillance of SARS-CoV-2 variants and the development of updated vaccines targeting emerging strains can help maintain vaccine effectiveness[32].

Implications of SARS-CoV-2 Variants and Future Research Directions

The emergence of SARS-CoV-2 variants with the potential to reduce vaccine effectiveness has raised concerns about the durability of vaccine-induced immunity. Ongoing research is needed to understand the implications of these variants for vaccine efficacy, as well as to develop updated vaccines and public health strategies[14, 33]. Evaluating the efficacy of current vaccines against emerging variants and determining the need for updated vaccines or booster doses. Developing next-generation vaccines targeting multiple viral antigens or incorporating conserved regions of the virus to provide broader protection against diverse strains. Investigating the role of T cell-mediated immunity in vaccine-induced protection and exploring strategies to enhance T cell responses. Assessing the long-term safety and effectiveness of COVID-19 vaccines in real-world settings, including populations not well-represented in clinical

trials, such as pregnant individuals, children, and individuals with specific comorbidities. Exploring novel vaccine platforms and delivery methods that can be more easily adapted to emerging viral strains, as well as strategies to improve vaccine accessibility and affordability[33, 34].

Conclusion

The development and deployment of COVID-19 vaccines represent an unprecedented achievement in the global response to the pandemic. The rapid pace of vaccine development and the diversity of vaccine platforms used have provided a range of effective and safe options for controlling viral transmission and reducing the impact of the disease. However, challenges remain in ensuring global vaccine access, addressing vaccine hesitancy, and adapting to emerging SARS-CoV-2 variants. Ongoing research, international collaboration, and investments in public health infrastructure are critical to address these challenges and ensure the continued effectiveness of vaccines in controlling the pandemic[24].

As we look to the future, the lessons learned from the COVID-19 vaccine development and deployment process can help inform the response to future pandemics and guide the advancement of vaccine technology and public health preparedness. The COVID-19 pandemic has underscored the importance of global cooperation, scientific innovation, and the value of vaccines in safeguarding public health.

References

1. Calina D, Docea AO, Petrakis D et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med 2020; 46: 3-16. DOI: 10.3892/ijmm.2020.4596
2. Yuen KS, Ye ZW, Fung SY et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40. DOI: 10.1186/s13578-020-00404-4
3. Li M, Wang H, Tian L et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy 2022; 7: 146. DOI: 10.1038/s41392-022-00996-y
4. Sadoff J, Le Gars M, Shukarev G et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine 2021; 384: 1824-1835. DOI: 10.1056/NEJMoa2034201
5. Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Review of Vaccines 2018; 17: 677-686. DOI: 10.1080/14760584.2018.1506702
6. Fang E, Liu X, Li M et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy 2022; 7: 94. DOI: 10.1038/s41392-022-00950-y
7. Kim J, Eygeris Y, Gupta M et al. Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews 2021; 170: 83-112. DOI: https://doi.org/10.1016/j.addr.2020.12.014
8. Travieso T, Li J, Mahesh S et al. The use of viral vectors in vaccine development. npj Vaccines 2022; 7: 75. DOI: 10.1038/s41541-022-00503-y
9. Mendonça SA, Lorincz R, Boucher P et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. npj Vaccines 2021; 6: 97. DOI: 10.1038/s41541-021-00356-x
10. Dicks MDJ, Spencer AJ, Edwards NJ et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLOS ONE 2012; 7: e40385. DOI: 10.1371/journal.pone.0040385
11. Huang Z, Xu S, Liu J et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Medicine 2022; 20: 400. DOI: 10.1186/s12916-022-02606-8
12. Lounis M, Rais MA, Bencherit D et al. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. Frontiers in Public Health 2022; 10.
13. Yang M-C, Wang C-C, Tang W-C et al. Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. PLOS ONE 2023; 18: e0283473. DOI: 10.1371/journal.pone.0283473
14. Bravo L, Smolenov I, Han HH et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 2022; 399: 461-472. DOI: 10.1016/S0140-6736(22)00055-1
15. Niebel D, Novak N, Wilhelmi J et al. Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. DOI: 10.3390/vaccines9090944

16.	Muñoz FM, Sher LD, Sabharwal C et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. New England Journal of Medicine 2023; 388: 621-634. DOI: 10.1056/NEJMoa2211031

17.	Cao L, Lou J, Chan SY et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine 2022; 28: 1715-1722. DOI: 10.1038/s41591-022-01877-1

18.	Swift MD, Breeher LE, Tande AJ et al. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clin Infect Dis 2021; 73: e1376-e1379. DOI: 10.1093/cid/ciab361

19.	Baden LR, El Sahly HM, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 2020; 384: 403-416. DOI: 10.1056/NEJMoa2035389

20.	Barros-Martins J, Hammerschmidt SI, Cossmann A et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine 2021; 27: 1525-1529. DOI: 10.1038/s41591-021-01449-9

21.	Abufares HI, Oyoun Alsoud L, Alqudah MAY et al. COVID-19 Vaccines, Effectiveness, and Immune Responses. DOI: 10.3390/ijms232315415

22.	Zhang Y, Belayachi J, Yang Y et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health 2022; 22: 1584. DOI: 10.1186/s12889-022-14016-9

23.	Shinde V, Bhikha S, Hoosain Z et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021; 384: 1899-1909. DOI: 10.1056/NEJMoa2103055

24.	Alam ST, Ahmed S, Ali SM et al. Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals. International Journal of Production Economics 2021; 239: 108193. DOI: https://doi.org/10.1016/j.ijpe.2021.108193

25.	Geng EH, Reid MJA, Goosby E et al. COVID-19 and global equity for health: The good, the bad, and the wicked. PLOS Medicine 2021; 18: e1003797. DOI: 10.1371/journal.pmed.1003797

26.	Reza HM, Sultana F, Bari R et al. Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk. The Lancet Regional Health - Southeast Asia 2023; 11. DOI: 10.1016/j.lansea.2023.100158

27.	Lazarus JV, Wyka K, White TM et al. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nature Communications 2022; 13: 3801. DOI: 10.1038/s41467-022-31441-x

28.	Chen Y, Liu Q, Zhou L et al. Emerging SARS-CoV-2 variants: Why, how, and what's next? Cell Insight 2022; 1: 100029. DOI: https://doi.org/10.1016/j.cellin.2022.100029

29.	David M, Kaci Kennedy M, Osondu O et al. Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective. BMJ Global Health 2020; 5: e003627. DOI: 10.1136/bmjgh-2020-003627

30.	Sarai K, Florence R, Rhiannon O et al. University patenting and licensing practices in the United Kingdom during the COVID-19 pandemic. medRxiv 2022; 2021.2009.2020.21263777. DOI: 10.1101/2021.09.20.21263777

s are also publicly accessible online via WhatDoTheyKnow.com. For further information please contact the corresponding author. https://www.whatdotheyknow.com/user/sarai_keestra https://www.whatdotheyknow.com/user/florence_rodgers?page=2

31.	ZM S, Id O, Y S. - Strengthening supply chain resilience during COVID-19: A case study of JD.com. Journal of Operations Management 2021; 18.

32.	Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine 2020; 38: 6194-6198. DOI: 10.1016/j.vaccine.2020.07.013

33.	Zabidi NZ, Liew HL, Farouk IA et al. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. DOI: 10.3390/v15040944

34.	Robinson PC, Liew DFL, Tanner HL et al. COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences 2022; 119: e2119893119. DOI: 10.1073/pnas.2119893119